Wet age-related macular degeneration (AMD) is an eye condition that threatens the middle of your eyesight. It’s caused when abnormal blood vessels in your eyes leak fluid, damaging the part of your ...

ALPHARETTA, Ga., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical (CLSD), Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...

People with a condition called wet age-related macular degeneration (AMD) often receive eye injections. These eye injections can help to improve vision and also stop the damage that causes vision to ...

Recently published Wet AMD Market Insights report includes a comprehensive understanding of current treatment practices, wet ...

Please provide your email address to receive an email when new articles are posted on . Driving distance was inversely associated with the average number of injections per year. Travel reimbursement ...

Resveratrol supplementation in wet AMD patients led to fewer aflibercept injections and reduced macular fibrosis progression over two years. Both treatment groups showed significant improvements in ...

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMD ARTEMIS ...

Adverum Biotechnologies Inc (NASDAQ:ADVM) released data from its ongoing LUNA Phase 2 trial for Ixo-vec in patients with wet age-related macular degeneration (AMD). The 26-week interim analysis was ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase ...

At least 20 million Americans ages 40 and older have age-related macular degeneration, and the threat posed by the vision-robbing condition will only grow larger as the population ages. Despite the ...